Autologous Immunotherapy

Autologous immunotherapy treats cancer and autoimmune diseases by utilizing and activating the patient’s immune system cells.

Autologous immunotherapy relies on the patient’s immune cells (T cells) to identify and attack cancer cells. Under this therapy, T cells are removed from the patient’s blood and sent to a laboratory. They are genetically modified there to express a specific receptor called a chimeric antigen receptor (CAR). The receptors allow the T cells to identify and act on cells carrying the target antigen. The modified T cells are then cultured in the laboratory and infused into the patient’s bloodstream. The present therapy is effective in the treatment of various types of cancer, such as acute lymphoblastic leukemia and some large B-cell lymphomas.

The procedure involves altering the usual cells in the tumor area to identify the immune system’s structure.